Tevogen Bio Holdings (TVGN)

• Market cap: $38.6M
• 1 day: -8.68%
• 5 days: -14.96%
• 1 month: 3.04%
• 3 months: 63.98%
• 6 months: -52.34%
• Year to date: -49.7%
• 1 year: -85.59%
• 5 years: -98.16%
• 10 years: -98.16%
• Sector: Healthcare
• Industry: Biotechnology

About: Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.

Employees: 18